HON vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Honeywell International Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-25.
Honeywell International Inc. · Industrials
$213.17
-14.5% upside to fair value
Grade D
VS
Johnson & Johnson · Healthcare
$230.69
+10.8% upside to fair value
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+10.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
HON |
JNJ |
| Current Price |
$213.17 |
$230.69 |
| Fair Value Estimate |
$182.35 |
$255.61 |
| Upside to Fair Value |
-14.5%
|
+10.8%
|
| Market Cap |
$135.1B |
$555.9B |
| Forward P/E |
33.0x
|
26.8x
|
| EV / EBITDA |
23.9x
|
18.5x
|
| Price / Sales |
3.7x
|
5.8x
|
| Price / FCF |
32.4x
|
28.2x
|
| Revenue Growth YoY |
-6.9%
|
+9.9%
|
| Gross Margin |
36.9%
|
69.1%
|
| Operating Margin |
14.9%
|
26.9%
|
| Return on Equity |
23.6%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.09%
|
3.54%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Honeywell International Inc. is a diversified industrial conglomerate operating across Aerospace Technologies, Building Automation, Process Automation and Technology, and Safety and Productivity Solutions. The company benefits from a strong leadership team with deep internal experience and a history of strategic acquisitions that have expanded its portfolio into high-growth areas such as aerospac…
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
HON |
JNJ |
| Zone Low |
$136.76 |
$191.71 |
| Zone High |
$155.00 |
$217.27 |
| In Buy Zone? |
No
|
No
|